STAAR Surgical reported first-quarter 2026 results in May 2026 and noted FDA approval expanding the EVO family of implantable collamer lens (ICL) indication to patients aged 45–60. The company framed the broader label as a way to increase addressable market for refractive surgeons offering ICL as an alternative to corneal laser procedures.
For ophthalmic and surgical device sales professionals, label expansions often matter more than a single quarter’s revenue print: they change which surgeons will discuss the technology, how practices market premium vision correction, and how territories are sized.
Commercial Implications for Reps
- Broader age bands can open conversations with surgeons who previously limited ICL to younger myopes
- Premium positioning still requires surgeon confidence, staff training, and patient selection discipline
- Territory plans may shift toward higher-volume refractive practices and away from pure research accounts
- Competitive messaging against laser platforms becomes a core skill—not just product features
What Employers Should Look For
Hiring managers should prioritize reps who can articulate surgeon adoption barriers honestly: staff workflow, patient counseling, and when ICL is not the right option. In interviews, strong candidates explain how they build referral funnels and measure adoption—not just quota attainment in a narrow niche.